Key Highlights
- Vizgen and Scale Biosciences (ScaleBio) partner to integrate single-cell and spatial genomics technologies.
- The collaboration aims to produce high-resolution data from brain tissue sections, enhancing neuroscience and cancer biology research.
- Three poster presentations by Vizgen at AGBT 2024, including a sponsored Women’s Networking Event featuring astronaut Kathleen Rubins.
Source: Business Wire
Notable Quotes
- “The unique combination of our technology and that of ScaleBio is capable of powering deep analysis to uncover a tissue’s composition and the roles and interactions of heterogeneous cell types within that tissue.” – Terry Lo, President and CEO at Vizgen
- “Our highly scalable single-cell omics platform, paired with Vizgen’s highly multiplexed, high resolution in situ platform, enables our customers to greatly enhance the types of biological insights they can generate.” – Giovanna Prout, President and CEO at ScaleBio
SoH's Take
This strategic partnership between Vizgen and Scale Biosciences represents a significant leap forward in the field of genomics, particularly in the areas of neuroscience and cancer biology. By combining Vizgen’s high-resolution in situ spatial genomics platform with ScaleBio’s scalable single-cell omics technologies, the collaboration is set to unlock new potentials in tissue composition analysis and cellular interaction studies. This integration not only facilitates the generation of high-resolution data from complex tissue sections but also promotes a more comprehensive understanding of cellular functions in health and disease. The shared commitment to innovation and accessibility in scientific research by Vizgen and ScaleBio underscores the importance of collaborative efforts in driving transformative advances in genomics. The upcoming presentations and events at the AGBT 2024 General Meeting will likely spotlight the practical applications and future directions of this partnership, setting a new standard for research in spatial and single-cell genomics.
